Celldex Therapeutics (DB:TCE2) - Cotización, noticias y análisis

Resumen de acción TCE2

Celldex Therapeutics, Inc. es una empresa biofarmacéutica dedicada al desarrollo de anticuerpos terapéuticos monoclonales y biespecíficos para el tratamiento de diversas enfermedades.

Acerca de la empresa

TCE2 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 72.38%

Análisis de riesgos

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Los accionistas han sido diluidos en el último año

Volatilidad del precio de la acción en los últimos 3 meses

Competidores de Celldex Therapeutics, Inc.

MorphoSys

XTRA:MOR

€2.5b

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€818.5m

Heidelberg Pharma

XTRA:HPHA

€140.3m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Celldex Therapeutics
Historical stock prices
Current Share Price	US$39.20
52 Week High	US$47.80
52 Week Low	US$21.20
Beta	1.56
1 Month Change	8.29%
3 Month Change	14.62%
1 Year Change	31.54%
3 Year Change	75.78%
5 Year Change	1,238.34%
Change since IPO	-28.99%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	TCE2	DE Biotechs	Mercado DE
7D	16.7%	1.8%	-0.3%
1Y	31.5%	-19.9%	2.8%

Rentabilidad vs. Industria: TCE2 superó al sector German Biotechs , que obtuvo un rendimiento del -24.4% el año pasado.

Rentabilidad vs. Mercado: TCE2 superó al mercado German, que obtuvo un rendimiento del -0.3% el año pasado.

Volatilidad de los precios

Is TCE2's price volatile compared to industry and market?
TCE2 volatility
TCE2 Average Weekly Movement	8.7%
Biotechs Industry Average Movement	5.2%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.3%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: TCE2 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de TCE2(8%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de German.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1983	160	Anthony Marucci	www.celldex.com

Celldex Therapeutics, Inc. es una empresa biofarmacéutica dedicada al desarrollo de anticuerpos terapéuticos monoclonales y biespecíficos para el tratamiento de diversas enfermedades. Sus fármacos candidatos incluyen terapias basadas en anticuerpos para tratar a pacientes con enfermedades inflamatorias, alérgicas, autoinmunes y otras enfermedades devastadoras. Los programas de desarrollo clínico de la empresa CDX-0159, un anticuerpo monoclonal de fase II que se une al receptor tirosina quinasa KIT e inhibe su actividad.

Resumen de fundamentos de Celldex Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Celldex Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de TCE2
Capitalización bursátil	€2.60b
Beneficios(TTM)	-€131.33m
Ingresos (TTM)	€6.39m

398.8x

Ratio precio-ventas (PS)

-19.4x

Ratio precio-beneficio (PE)

¿Está TCE2 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de TCE2
Ingresos	US$6.88m
Coste de los ingresos	US$118.01m
Beneficio bruto	-US$111.13m
Otros gastos	US$30.30m
Beneficios	-US$141.43m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-2.15
Margen bruto	-1,614.53%
Margen de beneficio neto	-2,054.76%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado TCE2 a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción TCE2

Recompensas

Análisis de riesgos

Competidores de Celldex Therapeutics, Inc.

XTRA:MOR

€2.5b

XTRA:BIO3

€1.4b

XTRA:FYB

€818.5m

XTRA:HPHA

€140.3m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Celldex Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 26, 2024

Recent updates

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Celldex Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 26, 2024

Full year 2023 earnings released: US$2.92 loss per share (vs US$2.40 loss in FY 2022)

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.475 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering.

Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

New major risk - Share price stability

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.57 loss in 3Q 2022)

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1B Results in Prurigo Nodularis At 12Th World Congress on Itch 2023

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.65 loss per share (vs US$0.77 loss in 2Q 2022)

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis

Now 22% undervalued after recent price drop

Celldex Therapeutics, Inc. Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023

Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of Cdx-585 in Patients with Advanced Malignancies

Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622

First quarter 2023 earnings released: US$0.62 loss per share (vs US$0.49 loss in 1Q 2022)

Full year 2022 earnings released: US$2.40 loss per share (vs US$1.65 loss in FY 2021)

Celldex Therapeutics, Inc. Announces Appointment of Rita Jain, M.D. to Board of Directors

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1B Study in Chronic Inducible Urticaria At Global Urticaria Forum 2022

Second quarter 2022 earnings released: US$0.77 loss per share (vs US$0.34 loss in 2Q 2021)

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces Board Appointments

First quarter 2022 earnings released: US$0.49 loss per share (vs US$0.42 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

Third quarter 2021 earnings released: US$0.45 loss per share (vs US$0.36 loss in 3Q 2020)

Celldex Therapeutics, Inc. Announces Initiation of CDX-0159 Subcutaneous Formulation Study

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.50 loss in 2Q 2020)

Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial

Celldex Therapeutics, Inc. Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021

First quarter 2021 earnings released: US$0.42 loss per share (vs US$0.72 loss in 1Q 2020)

Celldex Provides Reports Impairment for the Fourth Quarter of 2020

Full year 2020 earnings released: US$2.02 loss per share (vs US$3.51 loss in FY 2019)

New 90-day high: €24.00

Celldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN)

New 90-day high: €20.00

Celldex Therapeutics, Inc. Promotes Freddy Jimenez, to the Newly Created Position of Senior Vice President and General Counsel

Celldex Therapeutics, Inc. Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria

New 90-day high: €19.13

Celldex Therapeutics, Inc. Initiates Phase 1B Study of Cdx-0159 in Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Celldex Therapeutics, Inc.